Breast Cancer Core Needle Biopsy Market Size, Trends, Share, Growth | Report 2023-2032
Breast cancer core needle biopsy uses a hollow needle to remove a tube-shaped piece of tissue with a spring-loaded or vacuum-powered system. The tissue sample is used further for a more accurate laboratory assessment for precise determination of carcinogenicity. Growing incidence of breast cancers, recommendations for regular mammography, rising awareness, and numerous research studies are driving the market growth.
Breast cancer is the most prevalent type of cancer globally. According to WHO, there were around 2.3 million cases and 685 000 deaths globally in the year 2020 with around 7.8 million survivors. Effective and timely diagnosis is the only way to design efficient and personalized therapeutic regime with probability of survival being over 90%, given that the condition is identified early.
All breast cancer cases in low resource settings were treated by surgical removal of breast (mastectomy). The procedure has now evolved to partial removal of tissues that are cancerous in nature (lumpectomy) due to advancements in diagnostic techniques like mammography and biopsy. Researchers are working towards offering innovative solutions for early diagnosis to population in low resource setting. For instance, in April 2019, researchers at the Johns Hopkins University worked towards offering reusable, cost efficient, and sterile core biopsy device to patients. The research secured a Lemelson-MIT prize of USD 10,000.
Core needle biopsy is usually used to analyze non-palpable tumors to extract precise tissue sample. It facilitates the collection of multiple tumor tissue samples making the diagnosis process easier with an accuracy rate of around 90%. The accuracy of CNB increases with the tumor size and the number of tissue samples collected. At least four samples have to be collected to make a precise diagnosis.
Proteins are usually known as the business end of a genome. Proteins in tumors can now be analyzed with micro amounts of tissue sample obtained using a single core needle biopsy to profile proteins as well as its underlying genetic modifications. For instance, in February 2020, according to an article published by National Cancer Institute (NCI), combined molecular analyses is capable of analyzing tumors using micro amounts of tissue using micro-scaled approach. The technique was also used to gauge individual responses to therapy.
The heterogeneity in breast lesions necessitates the need for needle biopsy procedures to be guided by imaging technology such as an MRI, ultrasound, mammography, or a Computed Tomography (CT) scan. The imaging techniques are used appropriately to guide the core needle to collect tissue samples with utmost precision to avoid the possibility of misdiagnosis or over-diagnosis of the condition. For instance, in August 2022, researchers at the IMIM (Hospital del Mar Medical Research Institute), Spain, experimented a technique that involves breast biopsy guided by a contrast-mammography to be able to visualize lesions using MRI technology. The research is also published in the journal European Radiology.
Key Players
Market Segmentation
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Breast Cancer Core Needle Biopsy Market
5.1. COVID-19 Landscape: Breast Cancer Core Needle Biopsy Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Breast Cancer Core Needle Biopsy Market, By Technology
8.1. Breast Cancer Core Needle Biopsy Market, by Technology, 2023-2032
8.1.1. MRI-Based Breast Biopsy
8.1.1.1. Market Revenue and Forecast (2019-2032)
8.1.2. Ultrasound-Based Breast Biopsy
8.1.2.1. Market Revenue and Forecast (2019-2032)
8.1.3. Mammography-Based (Stereotactic) Breast Biopsy
8.1.3.1. Market Revenue and Forecast (2019-2032)
8.1.4. CT-Based Breast Biopsy
8.1.4.1. Market Revenue and Forecast (2019-2032)
8.1.5. Other Image Based Breast Biopsy
8.1.5.1. Market Revenue and Forecast (2019-2032)
Chapter 9. Global Breast Cancer Core Needle Biopsy Market, By End-use
9.1. Breast Cancer Core Needle Biopsy Market, by End-use, 2023-2032
9.1.1. Hospitals & Diagnostic Laboratories
9.1.1.1. Market Revenue and Forecast (2019-2032)
9.1.2. Pharmaceutical & Biotechnology companies
9.1.2.1. Market Revenue and Forecast (2019-2032)
9.1.3. Academic & Research Institutes
9.1.3.1. Market Revenue and Forecast (2019-2032)
Chapter 10. Global Breast Cancer Core Needle Biopsy Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Technology (2019-2032)
10.1.2. Market Revenue and Forecast, by End-use (2019-2032)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Technology (2019-2032)
10.1.3.2. Market Revenue and Forecast, by End-use (2019-2032)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Technology (2019-2032)
10.1.4.2. Market Revenue and Forecast, by End-use (2019-2032)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Technology (2019-2032)
10.2.2. Market Revenue and Forecast, by End-use (2019-2032)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Technology (2019-2032)
10.2.3.2. Market Revenue and Forecast, by End-use (2019-2032)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Technology (2019-2032)
10.2.4.2. Market Revenue and Forecast, by End-use (2019-2032)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Technology (2019-2032)
10.2.5.2. Market Revenue and Forecast, by End-use (2019-2032)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Technology (2019-2032)
10.2.6.2. Market Revenue and Forecast, by End-use (2019-2032)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Technology (2019-2032)
10.3.2. Market Revenue and Forecast, by End-use (2019-2032)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Technology (2019-2032)
10.3.3.2. Market Revenue and Forecast, by End-use (2019-2032)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Technology (2019-2032)
10.3.4.2. Market Revenue and Forecast, by End-use (2019-2032)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Technology (2019-2032)
10.3.5.2. Market Revenue and Forecast, by End-use (2019-2032)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Technology (2019-2032)
10.3.6.2. Market Revenue and Forecast, by End-use (2019-2032)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Technology (2019-2032)
10.4.2. Market Revenue and Forecast, by End-use (2019-2032)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Technology (2019-2032)
10.4.3.2. Market Revenue and Forecast, by End-use (2019-2032)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Technology (2019-2032)
10.4.4.2. Market Revenue and Forecast, by End-use (2019-2032)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Technology (2019-2032)
10.4.5.2. Market Revenue and Forecast, by End-use (2019-2032)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Technology (2019-2032)
10.4.6.2. Market Revenue and Forecast, by End-use (2019-2032)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Technology (2019-2032)
10.5.2. Market Revenue and Forecast, by End-use (2019-2032)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Technology (2019-2032)
10.5.3.2. Market Revenue and Forecast, by End-use (2019-2032)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Technology (2019-2032)
10.5.4.2. Market Revenue and Forecast, by End-use (2019-2032)
Chapter 11. Company Profiles
11.1. Intact Medical Corporation
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Ethicon Endo Surgery
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Galini SRL
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Leica Biosystems Nussloch GmbH
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. LTE Scientific
11.5. Hologic Inc.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Argon Medical Devices
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Encapsule Medical Devices LLC.
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Cook Medical Incorporated
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Becton & Dickinson Company
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. C.R. Bard, Inc.
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers